News & Perspective

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 01, 2007

Nov 01, 2007

THE PANDEMIC VACCINE PUZZLE Part 6: Looking to novel vaccine technologies

Editor's note: This is the sixth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.

Oct 30, 2007

Oct 30, 2007

THE PANDEMIC VACCINE PUZZLE Part 4: The promise and problems of adjuvants

Editor's note: This is the fourth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Oct 29, 2007

Oct 29, 2007

THE PANDEMIC VACCINE PUZZLE Part 3: H5N1 poses major immunologic challenges

Editor's note: This is the third in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Sep 26, 2007

Sep 26, 2007

IOM calls for new research on safety garb for health workers

(CIDRAP News) – An Institute of Medicine (IOM) committee that studied issues concerning personal protective equipment (PPE) for healthcare workers in an influenza pandemic is calling for renewed efforts to learn how influenza viruses spread, promote proper use of PPE, and improve the equipment itself.

Aug 27, 2007

Aug 27, 2007

Trial results for Glaxo's H5N1 vaccine released

(CIDRAP News) – The full results of a trial of GlaxoSmithKline's (GSK's) H5N1 influenza vaccine were released recently, showing that the vaccine in combination with an adjuvant produced an acceptable immune response at a low dose and may provide cross-protection against nonmatching H5N1 strains.

Jul 19, 2007

Jul 19, 2007

HHS updates pandemic stockpile totals and planning efforts

(CIDRAP News) – In an update on the nation's pandemic preparedness efforts, the US Department of Health and Human Services (HHS) yesterday said it had stockpiled enough H5N1 avian influenza vaccine to protect about 6 million people and that federal and state supplies contain enough antiviral medication to treat more than 48 million.

Jul 17, 2007

Jul 17, 2007

White House issues 1-year status report on pandemic planning

(CIDRAP News) – The White House Homeland Security Council today released a 1-year update on the federal government's pandemic influenza preparedness strategy, reporting that it has met 86% of the objectives it set for itself a year ago.

Jun 20, 2007

Jun 20, 2007

Japanese to study behavioral effects of Tamiflu

(CIDRAP News) – The company that markets oseltamivir (Tamiflu) in Japan has announced it will launch new studies to explore whether the antiviral drug contributes to adverse psychiatric and neurologic events in teenagers.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»